3 days Ago By ABMN Staff
Eledon Pharmaceuticals, Inc. ( NASDAQ:ELDN – Free Report ) – Equities researchers at Cantor Fitzgerald increased their FY2024 earnings per share (EPS) estimates for shares of Eledon Pharmaceuticals in a research note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst P.
Stavropoulos now anticipates that the company will earn ($0.28) per share for the year, up from their prior forecast of ($1.14).
The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.72) per share. Eledon Pharmaceuticals Stock Down 2.
5 % Shares of NASDAQ ELDN opened at $3.90 on Monday. Eledon Pharmaceuticals has a twelve month low of $1.
11 and a twelve month high of $5.54. The stock has a market cap of $154.
67 million, a price-to-earnings ratio of -1.94 and a beta of 0.76.
The company’s fifty day moving average is $3.29 and its 200-day moving average is $2.91.
Institutional Investors Weigh In On Eledon Pharmaceuticals Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in Eledon Pharmaceuticals by 39.
4% during the 1st quarter. Vanguard Group Inc. now owns 969,121 shares of the company’s stock worth $1,996,000 after acquiring an additional 273,703 shares during the last quarter.
CM Management LLC grew its position in Eledon Pharmaceuticals by 14.3% in the first quarter. CM Management LLC now owns 160,000 shares of the company’s stock valued at $330,000 after purchasing an additional 20,000 shares in the last quarter.
Marco Investment Management LLC increased its stake in Eledon Pharmaceuticals by 22.3% in the 2nd quarter. Marco Investment Management LLC now owns 30,344 shares of the company’s stock valued at $80,000 after buying an additional 5,535 shares during the last quarter.
Dimensional Fund Advisors LP bought a new stake in Eledon Pharmaceuticals during the 2nd quarter worth about $80,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Eledon Pharmaceuticals by 57.1% during the 2nd quarter.
Renaissance Technologies LLC now owns 136,773 shares of the company’s stock worth $361,000 after buying an additional 49,704 shares during the last quarter. Institutional investors own 56.77% of the company’s stock.
About Eledon Pharmaceuticals ( Get Free Report ) Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). See Also Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
